Achieving blood pressure targets in the management of hypertension

Blood Pressure, Supplement

Volumn 10, Issue 2, 2001, Pages 6-12

  Waeber, B ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

Angiotensin II receptor antagonists; Hypertension; Irbesartan; Tolerability

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; HYDROCHLOROTHIAZIDE; IRBESARTAN; ANGIOTENSIN RECEPTOR; ANTIHYPERTENSIVE AGENT;

BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; CONFERENCE PAPER; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERABILITY; HUMAN; HYPERTENSION; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; BLOOD PRESSURE; DISEASE MANAGEMENT; DRUG ANTAGONISM; DRUG COMBINATION; DRUG EFFECT; REVIEW; TREATMENT FAILURE;

ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; DISEASE MANAGEMENT; DRUG THERAPY, COMBINATION; HUMANS; HYPERTENSION; RECEPTORS, ANGIOTENSIN; TREATMENT FAILURE;

EID: 0035230230     PISSN: 08038023     EISSN: None     Source Type: Journal    
DOI: 10.1080/080370501750275839-1     Document Type: Conference Paper

References (32)

1. The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure
2. Blood pressure screening, management and control in England: Results from the health survey for England 1994
3. Hypertension awareness, treatment and control in the community: Is the 'rule of halves' still valid?
4. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients
5. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomized trial
6. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38
7. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39
8. Treatment of isolated systolic hypertension in the elderly: Further evidence from the systolic hypertension in Europe (Syst-Eur) trial
9. Antihypertensive drug therapy and survival by treatment status in a national survey
10. Blood pressure, systolic and diastolic, and cardiovascular risks
11. 1999 World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension
12. Mortality in patients of the Glasgow Blood Pressure Clinic
13. Blood pressure and end-stage renal disease in men
14. Perceived symptoms amongst hypertensive patients in routine clinical practice - A population-based study
15. Association between antihypertensive drug use and hypoglycemia: A case-control study of diabetic users of insulin or sulfonylureas
16. Task Force IV: Clinical use of ambulatory blood pressure monitoring
17. Blood-pressure control in the hypertensive population
18. Mortality rates in treated hypertensive men with additional risk factors are high but can be reduced: A randomized intervention study
19. Optimisation of antihypertensive treatment by crossover rotation of four major classes
20. Comparative antihypertensive efficacy of angiotensin receptor inhibitors (ARBs)
21. Newly emerging pharmacologic differences in angiotensin II receptor blockers
22. Dose-related antihypertensive effects of irbesartan in patients with mild-to-moderate hypertension
23. Clinical overview of irbesartan: Expanding the therapeutic window in hypertension
24. The longterm antihypertensive activity and tolerability of irbesartan with hydrochlorothiazide
25. Matrix study of irbesartan with hydrochlorothiazide in mild-to-moderate hypertension
26. Headache in mild-to-moderate hypertension and its reduction by irbesartan therapy
27. Commentary: Angiotensin II receptor blockers: Equal or preferred substitutes for ACE inhibitors?
28. Rate and extent of left ventricular hypertrophy regression: A comparison of angiotensin II blockade with irbesartan and β-blockade
29. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: Randomised trial - The losartan heart failure survival study ELITE II
30. Dose-related beneficial long-term hemodynamic and clinical efficacy of irbesartan in heart failure
31. Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy: A review of the literature and pathophysiology
32. Angiotensin II receptor blockade and end-organ protection